Division of Neuroradiology, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
AJNR Am J Neuroradiol. 2013 Aug;34(8):1528-34. doi: 10.3174/ajnr.A3434. Epub 2013 Feb 28.
The presence of active contrast extravasation at CTA predicts hematoma expansion and in-hospital mortality in patients with nontraumatic intracerebral hemorrhage. This study aims to determine the frequency and predictive value of the contrast extravasation in patients with aSDH.
We retrospectively reviewed 157 consecutive patients who presented to our emergency department over a 9-year period with aSDH and underwent CTA at admission and a follow-up NCCT within 48 hours. Two experienced readers, blinded to clinical data, reviewed the CTAs to assess for the presence of contrast extravasation. Medical records were reviewed for baseline clinical characteristics and in-hospital mortality. aSDH maximum width in the axial plane was measured on both baseline and follow-up NCCTs, with hematoma expansion defined as >20% increase from baseline.
Active contrast extravasation was identified in 30 of 199 discrete aSDHs (15.1%), with excellent interobserver agreement (κ = 0.80; 95% CI, 0.7-0.9). The presence of contrast extravasation indicated a significantly increased risk of hematoma expansion (odds ratio, 4.5; 95% CI, 2.0-10.1; P = .0001) and in-hospital mortality (odds ratio, 7.6; 95% CI, 2.6-22.3; P = 0.0004). In a multivariate analysis controlled for standard risk factors, the presence of contrast extravasation was an independent predictor of aSDH expansion (P = .001) and in-hospital mortality (P = .0003).
Contrast extravasation stratifies patients with aSDH into those at high risk and those at low risk of hematoma expansion and in-hospital mortality. This distinction could affect patient treatment, clinical trial selection, and possible surgical intervention.
CTA 上存在活跃的对比剂外渗可预测非创伤性颅内出血患者的血肿扩大和住院死亡率。本研究旨在确定急性硬膜下血肿(aSDH)患者中对比剂外渗的频率及其预测价值。
我们回顾性分析了在过去 9 年期间因 aSDH 就诊于我院急诊科的 157 例连续患者的资料,这些患者在入院时和 48 小时内行 CTA 检查,并在随后的 NCCT 上进行了随访。两名经验丰富的读者在不知道临床数据的情况下对 CTAs 进行了评估,以评估是否存在对比剂外渗。查阅病历记录以评估基线临床特征和住院死亡率。在基线和随访 NCCT 上测量轴位最大 aSDH 宽度,血肿扩大定义为与基线相比增加>20%。
在 199 个离散的 aSDH 中,有 30 个(15.1%)显示出活跃的对比剂外渗,观察者间一致性很好(κ=0.80;95%置信区间,0.7-0.9)。对比剂外渗的存在表明血肿扩大的风险显著增加(优势比,4.5;95%置信区间,2.0-10.1;P=0.0001)和住院死亡率(优势比,7.6;95%置信区间,2.6-22.3;P=0.0004)。在多变量分析中,控制了标准风险因素后,对比剂外渗是 aSDH 扩大的独立预测因子(P=0.001)和住院死亡率(P=0.0003)。
对比剂外渗将 aSDH 患者分为血肿扩大和住院死亡率高风险和低风险的患者。这种区分可能会影响患者的治疗、临床试验选择和可能的手术干预。